BillionaireClubCollc
  • News
  • Notifications
  • Shop
  • Cart
  • Media
  • Advertise with Us
  • Profile
  • Groups
  • Games
  • My Story
  • Chat
  • Contact Us
home shop notifications more
Signin
  •  Profile
  •  Sign Out
Skip to content

Billionaire Club Co LLC

Believe It and You Will Achieve It

Primary Menu
  • Home
  • Politics
  • TSR
  • Anime
  • Michael Jordan vs.Lebron James
  • Crypto
  • Soccer
  • Dating
  • Airplanes
  • Forex
  • Tax
  • New Movies Coming Soon
  • Games
  • CRYPTO INSURANCE
  • Sport
  • MEMES
  • K-POP
  • AI
  • The Bahamas
  • Digital NoMad
  • Joke of the Day
  • RapVerse
  • Stocks
  • SPORTS BETTING
  • Glamour
  • Beauty
  • Travel
  • Celebrity Net Worth
  • TMZ
  • Lotto
  • COVD-19
  • Fitness
  • The Bible is REAL
  • OutDoor Activity
  • Lifestyle
  • Culture
  • Boxing
  • Food
  • LGBTQ
  • Poetry
  • Music
  • Misc
  • Open Source
  • NASA
  • Science
  • Natural & Holstict Med
  • Gardening
  • DYI
  • History
  • Art
  • Education
  • Pets
  • Aliens
  • Astrology
  • Farming and LiveStock
  • LAW
  • Fast & Furious
  • Fishing & Hunting
  • Health
  • Credit Repair
  • Grants
  • All things legal
  • Reality TV
  • Africa Today
  • China Today
  • "DUMB SHIT.."
  • Stocks

Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue

Igor Golovniov / SOPA Images / LightRocket via Getty Images

Key TakeawaysSales at Abbott Laboratories' diagnostics unit dropped in the second quarter as demand for COVID-19 tests slumped.The company beat profit and sales estimates on strong sales of its medical devices.Abbott raised its full-year profit and organic sales growth outlooks.
Shares of Abbott Laboratories (ABT) declined in intraday trading Thursday as the healthcare products maker’s sales of COVID-19 tests slumped with the pandemic ending.The company reported second-quarter adjusted earnings per share (EPS) of $1.14, with revenue rising 4% year-over-year to $10.38 billion. Both beat estimates. The results were boosted by sales at Abbott’s medical devices segment, which were up 10.2% to $4.73 billion. Diabetes care product sales, which include those for its popular Freestyle Libre glucose-monitoring device, jumped 15.8% to $1.65 billion.However, sales at its diagnostics unit fell 5.3% to $2.20 billion as COVID-19 test revenue slumped to $102 million from $263 million a year ago. 'Positive Momentum Heading Into the Second Half'Chief Executive Officer (CEO) Robert Ford said Abbott has “a lot of positive momentum heading into the second half of the year,” and that’s why it is raising its full-year guidance.The company now sees 2024 adjusted EPS of $4.61 to $4.71, up from the earlier outlook of $4.55 to $4.70. It also raised the bottom of its organic sales growth range forecast, excluding COVID-19-related testing sales, to 9.5% to 10.0% from the previous guidance of 8.5% to 10.0%. Abbott Laboratories shares were down 3.5% as of 1:55 p.m. ET Thursday to $101.04, near their lows for the year. Read the original article on Investopedia.

Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!

Source link

Share
What's your thought on the article, write a comment
0 Comments
×

Sign In to perform this Activity

Sign in
×

Account Frozen

Your account is frozen. You can still view content but cannot interact with it.

Please go to your settings to update your account status.

Open Profile Settings

Ads

  • Original Billionaire128 Cuffed Beanie

    $ 19.50
  • Billionaire128 Liquid Gold Yoga Leggings

    $ 42.00
  • Billionaire128 Liquid Gold Sublimation Dress

    $ 36.50
  • News Social

    • Facebook
    • Twitter
    • Facebook
    • Twitter
    Copyright © 2024 Billionaire Club Co LLC. All rights reserved